The role of ATP and adenosine in the brain under normoxic and ischemic conditions

Purinergic Signalling

Volumn 3, Issue 4, 2007, Pages 299-310

  Pedata, Felicita ^a   Melani, A ^b   Pugliese, A M ^a   Coppi, E ^a   Cipriani, S ^a   Traini, C ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Adenosine; Adenosine A2A receptors; ATP; Ecto ATPase inhibitors; Ischemia; P2 purinergic receptors

Indexed keywords

EID: 36248955454     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-007-9085-8     Document Type: Article

References (142)

1. Burnstock G, Dumsday B, Smythe A (1972) Atropine resistant excitation of the urinary bladder: The possibility of transmission via nerves releasing a purine nucleotide. Br J Pharmacol 44:451-461
2. Burnstock G, Cocks T, Kasakov L et al (1978) Direct evidence for ATP release from non-adrenergic, non-cholinergic ("purinergic") nerves in the guinea-pig taenia coli and bladder. Eur J Pharmacol 49:145-149
3. Fredholm BB, IJzerman AP, Jacobson KA et al (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
4. Abbracchio MP, Burnstock G (1994) Purinoceptors: Are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64:445-475
5. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013-1067
6. Ciana P, Fumagalli M, Trincavelli ML et al (2006) The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 25:4615-4627
7. Cunha RA, Sebastiao AM, Ribeiro JA (1998) Inhibition by ATP of hippocampal synaptic transmission requires localized extracellular catabolism by ecto-nucleotidases into adenosine and channeling to adenosine A1 receptors. J Neurosci 18:1987-1995
8. Dunwiddie TV, Diao L, Proctor WR (1997) Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J Neurosci 17:7673-7682
9. O'Kane EM, Stone TW (1998) Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro. Eur J Pharmacol 362:17-25
10. Masino SA, Diao L, Illes P et al (2002) Modulation of hippocampal glutamatergic transmission by ATP is dependent on adenosine A1 receptors. J Pharmacol Exp Ther 303:356-363
11. Zimmermann H, Braun N (1996) Extracellular metabolism of nucleotides in the nervous system. J Auton Pharmacol 16:397-400
12. Rodrigues RJ, Almeida T, Richardson PJ et al (2005) Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J Neurosci 25:6286-6295
13. Mendoza-Fernandez V, Andrew RD, Barajas-Lopez C (2000) ATP inhibits glutamate synaptic release by acting at P2Y receptors in pyramidal neurons of hippocampal slices. J Pharmacol Exp Ther 293:172-179
14. Luthardt J, Borvendeg SJ, Sperlagh B et al (2003) P2Y(1) receptor activation inhibits NMDA receptor-channels in layer V pyramidal neurons of the rat prefrontal and parietal cortex. Neurochem Int 42:161-172
15. Coppi E, Pugliese AM, Stephan H et al (2007) Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices. Purinergic Signalling 3:203
16. Zimmermann H, Braun N, Kegel B et al (1998) New insights into molecular structure and function of ectonucleotidases in the nervous system. Neurochem Int 32:421-425
17. Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 362:299-309
18. Iqbal J, Vollmayer P, Braun N et al (2007) A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDase) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signalling 1:349-358
19. Kukulski F, Komoszynski M (2003) Purification and characterization of NTPDase1 (ecto-apyrase) and NTPDase2 (ecto-ATPase) from porcine brain cortex synaptosomes. Eur J Biochem 270:3447-3454
20. Muller CE, Iqbal J, Baqi Y et al (2006) Polyoxometalates-a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorg Med Chem Lett 16:5943-5947
21. Wieraszko A, Seyfried TN (1989) ATP-induced synaptic potentiation in hippocampal slices. Brain Res 491:356-359
22. Fujii S, Kato H, Furuse H et al (1995) The mechanism of ATP-induced long-term potentiation involves extracellular phosphorylation of membrane proteins in guinea-pig hippocampal CA1 neurons. Neurosci Lett 187:130-132
23. Fujii S, Kato H, Kuroda Y (1999) Extracellular adenosine 5′-triphosphate plus activation of glutamatergic receptors induces long-term potentiation in CA1 neurons of guinea pig hippocampal slices. Neurosci Lett 276:21-24
24. Fujii S, Kato H, Kuroda Y (2002) Cooperativity between extracellular adenosine 5′-triphosphate and activation of N-methyl-D-aspartate receptors in long-term potentiation induction in hippocampal CA1 neurons. Neuroscience 113:617-628
25. O'Kane EM, Stone TW (2000) Characterisation of ATP-induced facilitation of transmission in rat hippocampus. Eur J Pharmacol 409:159-166
26. Abrams TW, Kandel ER (1988) Is contiguity detection in classical conditioning a system or a cellular property? Learning in Aplysia suggests a possible molecular site. Trends Neurosci 11:128-135
27. Pankratov Y, Castro E, Miras-Portugal MT et al (1998) A purinergic component of the excitatory postsynaptic current mediated by P2X receptors in the CA1 neurons of the rat hippocampus. Eur J Neurosci 10:3898-3902
28. Juranyi Z, Sperlagh B, Vizi ES (1999) Involvement of P2 purinoceptors and the nitric oxide pathway in [3H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. Brain Res 823:183-190
29. Melani A, Turchi D, Vannucchi MG et al (2005) ATP extracellular concentrations are increased in the rat striatum during in vivo ischemia. Neurochem Int 47:442-448
30. Amadio S, D'Ambrosi N, Cavaliere F et al (2002) P2 receptor modulation and cytotoxic function in cultured CNS neurons. Neuropharmacology 42:489-501
31. Cavaliere F, D'Ambrosi N, Ciotti MT et al (2001) Glucose deprivation and chemical hypoxia: Neuroprotection by P2 receptor antagonists. Neurochem Int 38:189-197
32. Volonte C, Merlo D (1996) Selected P2 purinoceptor modulators prevent glutamate-evoked cytotoxicity in cultured cerebellar granule neurons. J Neurosci Res 45:183-193
33. Volonte C, Ciotti MT, D'Ambrosi N et al (1999) Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones. Neuropharmacology 38:1335-1342
34. Ryu JK, Kim J, Choi SH et al (2002) ATP-induced in vivo neurotoxicity in the rat striatum via P2 receptors. Neuroreport 13:1611-1615
35. Kharlamov A, Jones SC, Kim DK (2002) Suramin reduces infarct volume in a model of focal brain ischemia in rats. Exp Brain Res 147:353-359
36. Melani A, Amadio S, Gianfriddo M et al (2006) P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. J Cereb Blood Flow Metab 26:974-982
37. Lammer A, Gunther A, Beck A et al (2006) Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-induced injury in rats. Eur J Neurosci 23:2824-2828
38. Marrelli SP, Khorovets A, Johnson TD et al (1999) P2 purinoceptor-mediated dilations in the rat middle cerebral artery after ischemia-reperfusion. Am J Physiol 276:H33-H41
39. Lahiri P, Chaudhuri U, Chattopadhyay A et al (2005) Structural insights in platelet receptor synergism-antiplatelet therapy in post-ischemic cerebrovascular events. Blood Cells Mol Dis 34:248-256
40. Ziegler S, Schillinger M, Funk M et al (2005) Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 36:1394-1399
41. Neary JT (2000) Trophic actions of extracellular ATP: Gene expression profiling by DNA array analysis. J Auton Nerv Syst 81:200-204
42. Rathbone MP, DeForge S, Deluca B et al (1992) Purinergic stimulation of cell division and differentiation: Mechanisms and pharmacological implications. Med Hypotheses 37:213-219
43. Franke H, Illes P (2006) Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmacol Ther 109:297-324
44. Mishrda SK, Braun N, Shukla V et al (2006) Extracellular nucleotide signaling in adult neural stem cells: Synergism with growth factor-mediated cellular proliferation. Development 133:675-684
45. Kawano S, Otsu K, Kuruma A et al (2006) ATP autocrine/paracrine signaling induces calcium oscillations and NFAT activation in human mesenchymal stem cells. Cell Calcium 39:313-324
46. Coppi E, Pugliese AM, Urbani S et al (2007) ATP modulates cell proliferation and elicits two different electrophysiological responses in human mesenchymal stem cells. Stem Cells 25:1840-1849
47. Scholzke MN, Schwaninger M (2007) Transcriptional regulation of neurogenesis: Potential mechanisms in cerebral ischemia. J Mol Med 85:577-588
48. Latini S, Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79:463-484
49. von Lubitz DK, Lin RC, Bischofberger N et al (1999) Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. Eur J Pharmacol 369:313-317
50. Yawo H, Chuhma N (1993) Preferential inhibition of omega-conotoxin-sensitive presynaptic Ca2+ channels by adenosine autoreceptors. Nature 365:256-258
51. Wu LG, Saggau P (1994) Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus. Neuron 12:1139-1148
52. Prince DA, Stevens CF (1992) Adenosine decreases neurotransmitter release at central synapses. Proc Natl Acad Sci USA 89:8586-8590
53. Fredholm BB, Dunwiddie TV (1988) How does adenosine inhibit transmitter release? Trends Pharmacol Sci 9:130-134
54. Burke SP, Nadler JV (1988) Regulation of glutamate and aspartate release from slices of the hippocampal CA1 area: Effects of adenosine and baclofen. J Neurochem 51:1541-1551
55. Corradetti R, Lo CG, Moroni F et al (1984) Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol 104:19-26
56. Lupica CR, Proctor WR, Dunwiddie TV (1992) Presynaptic inhibition of excitatory synaptic transmission by adenosine in rat hippocampus: analysis of unitary EPSP variance measured by whole-cell recording. J Neurosci 12:3753-3764
57. Takigawa T, Alzheimer C (1999) G protein-activated inwardly rectifying K+ (GIRK) currents in dendrites of rat neocortical pyramidal cells. J Physiol 517(Pt 2):385-390
58. Takigawa T, Alzheimer C (2002) Phasic and tonic attenuation of EPSPs by inward rectifier K+ channels in rat hippocampal pyramidal cells. J Physiol 539:67-75
59. Latini S, Bordoni F, Corradetti R et al (1999) Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 128:1035-1044
60. Latini S, Bordoni F, Pedata F et al (1999) Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 127:729-739
61. Moore KA, Nicoll RA, Schmitz D (2003) Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses. Proc Natl Acad Sci USA 100:14397-14402
62. Pedata F, Pepeu G, Spignoli G (1984) Biphasic effect of methylxanthines on acetylcholine release from electrically-stimulated brain slices. Br J Pharmacol 83:69-73
63. Latini S, Pazzagli M, Pepeu G et al (1996) A2 adenosine receptors: Their presence and neuromodulatory role in the central nervous system. Gen Pharmacol 27:925-933
64. Sebastiao AM, Ribeiro JA (1996) Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 48:167-189
65. Spignoli G, Pedata F, Pepeu G (1984) A1 and A2 adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol 97:341-342
66. Cunha RA, Johansson B, Fredholm BB et al (1995) Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Lett 196:41-44
67. Cunha RA, Johansson B, van der Ploeg I et al (1994) Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res 649:208-216
68. Dixon AK, Widdowson L, Richardson PJ (1997) Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum. J Neurochem 69:315-321
69. Stone TW, Nikbakth M-R, O'Kane EM (2004) Adenosine and purines. In: Riedel G, Platt B (eds) From messengers to molecules: Memories are made of these. Kluwer Academic/Plenum, New York, p 196-223
70. Popoli P, Betto P, Reggio R et al (1995) Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 287:215-217
71. + -evoked glutamate release in vivo in young and aged rats. Neuroreport 10:687-691
72. Corsi C, Melani A, Bianchi L et al (2000) Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 11:2591-2595
73. Ross GW, Abbott RD, Petrovitch H et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679
74. Ascherio A, Zhang SM, Hernan MA et al (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
75. Costenla AR, Lopes LV, de Mendonca A et al (2001) A functional role for adenosine A3 receptors: Modulation of synaptic plasticity in the rat hippocampus. Neurosci Lett 302:53-57
76. Macek TA, Schaffhauser H, Conn PJ (1998) Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci 18:6138-6146
77. Fleming KM, Mogul DJ (1997) Adenosine A3 receptors potentiate hippocampal calcium current by a PKA-dependent/PKC-independent pathway. Neuropharmacology 36:353-362
78. Laudadio MA, Psarropoulou C (2004) The A3 adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat hippocampal slices. Epilepsy Res 59:83-94
79. Etherington LA, Frenguelli BG (2004) Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent manner. Eur J Neurosci 19:2539-2550
80. Brand A, Vissiennon Z, Eschke D et al (2001) Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons. Neuropharmacology 40:85-95
81. Pugliese AM, Latini S, Corradetti R et al (2003) Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: Role of adenosine receptors. Br J Pharmacol 140:305-314
82. Melani A, Pantoni L, Corsi C et al (1999) Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: Correlations with neurological deficit and histopathological damage. Stroke 30:2448-2454
83. Melani A, Pantoni L, Bordoni F et al (2003) The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 959:243-250
84. Latini S, Bordoni F, Corradetti R et al (1998) Temporal correlation between adenosine outflow and synaptic potential inhibition in rat hippocampal slices during ischemia-like conditions. Brain Res 794:325-328
85. Pearson T, Damian K, Lynas RE et al (2006) Sustained elevation of extracellular adenosine and activation of A1 receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. J Neurochem 97:1357-1368
86. Dux E, Fastbom J, Ungerstedt U et al (1990) Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res 516:248-256
87. Phillis JW, Smith-Barbour M, O'Regan MH et al (1994) Amino acid and purine release in rat brain following temporary middle cerebral artery occlusion. Neurochem Res 19:1125-1130
88. Frenguelli BG, Wigmore G, Llaudet E et al (2007) Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. J Neurochem 101:1400-1413
89. Phillis JW, O'Regan MH (1989) Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. Brain Res Bull 22:537-540
90. Lin Y, Phillis JW (1992) Deoxycoformycin and oxypurinol: Protection against focal ischemic brain injury in the rat. Brain Res 571:272-280
91. DeLeo J, Schubert P, Kreutzberg GW (1988) Protection against ischemic brain damage using propentofylline in gerbils. Stroke 19:1535-1539
92. Parkinson FE, Xiong W, Zamzow CR (2005) Astrocytes and neurons: different roles in regulating adenosine levels. Neurol Res 27:153-160
93. Kitagawa H, Mori A, Shimada J et al (2002) Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol Res 24:317-323
94. Pedata F, Latini S, Pugliese AM et al (1993) Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions. J Neurochem 61:284-289
95. Choi DW (1990) Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists. Stroke 21:III20-III22
96. Greene RW, Haas HL (1991) The electrophysiology of adenosine in the mammalian central nervous system. Prog Neurobiol 36:329-341
97. Tominaga K, Shibata S, Watanabe S (1992) A neuroprotective effect of adenosine A1-receptor agonists on ischemia-induced decrease in 2-deoxyglucose uptake in rat hippocampal slices. Neurosci Lett 145:67-70
98. Gourine AV, Dale N, Gourine VN et al (2004) Fever in systemic inflammation: Roles of purines. Front Biosci 9:1011-1022
99. von Lubitz DK (2001) Adenosine in the treatment of stroke: Yes, maybe, or absolutely not? Expert Opin Invest Drugs 10:619-632
100. Pearson T, Currie AJ, Etherington LA et al (2003) Plasticity of purine release during cerebral ischemia: Clinical implications? J Cell Mol Med 7:362-375
101. Jarrott DM, Domer FR (1980) A gerbil model of cerebral ischemia suitable for drug evaluation. Stroke 11:203-209
102. Rudolphi KA, Keil M, Fastbom J et al (1989) Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci Lett 103:275-280
103. Jacobson KA, von Lubitz DK, Daly JW et al (1996) Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108-113
104. Williams M (1993) Purinergic drugs: Opportunities in the 1990s. Drug Dev Res 28:438
105. von Lubitz DK, Lin RC, Paul IA et al (1996) Postischemic administration of adenosine amine congener (ADAC): Analysis of recovery in gerbils. Eur J Pharmacol 316:171-179
106. Phillis JW, Goshgarian HG (2001) Adenosine and neurotrauma: Therapeutic perspectives. Neurol Res 23:183-189
107. Gao Y, Phillis JW (1994) CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci 55:L61-L65
108. Bona E, Aden U, Gilland E et al (1997) Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists. Neuropharmacology 36:1327-1338
109. Monopoli A, Lozza G, Forlani A et al (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9:3955-3959
110. Pedata F, Gianfriddo M, Turchi D et al (2005) The protective effect of adenosine A2A receptor antagonism in cerebral ischemia. Neurol Res 27:169-174
111. Melani A, Gianfriddo M, Vannucchi MG et al (2006) The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 1073-1074:470-480
112. Chen JF, Huang Z, Ma J et al (1999) A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200
113. Marcoli M, Raiteri L, Bonfanti A et al (2003) Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45:201-210
114. O'Regan MH, Simpson RE, Perkins LM et al (1992) The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Lett 138:169-172
115. Simpson RE, O'Regan MH, Perkins LM et al (1992) Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: Effects of adenosine receptor agonists and antagonists. J Neurochem 58:1683-1690
116. Fiebich BL, Biber K, Lieb K et al (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2A-receptors. Glia 18:152-160
117. Saura J, Angulo E, Ejarque A et al (2005) Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95:919-929
118. Lee YC, Chien CL, Sun CN et al (2003) Characterization of the rat A2A adenosine receptor gene: A 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. Eur J Neurosci 18:1786-1796
119. Nishizaki T, Nagai K, Nomura T et al (2002) A new neuromodulatory pathway with a glial contribution mediated via A2A adenosine receptors. Glia 39:133-147
120. Pintor A, Galluzzo M, Grieco R et al (2004) Adenosine A2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89:152-156
121. Irving EA, Barone FC, Reith AD et al (2000) Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 77:65-75
122. Wu DC, Ye W, Che XM et al (2000) Activation of mitogen-activated protein kinases after permanent cerebral artery occlusion in mouse brain. J Cereb Blood Flow Metab 20:1320-1330
123. Barone FC, Irving EA, Ray AM et al (2001) Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev 21:129-145
124. Gao Y, Signore AP, Yin W et al (2005) Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J Cereb Blood Flow Metab 25:694-712
125. Kawasaki H, Morooka T, Shimohama S et al (1997) Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 272:18518-18521
126. Trincavelli ML, Melani A, Guidi S et al (2007) Regulation of A2A adenosine receptor expression and functioning following permanent focal ischemia in rat brain. J Neurochem. DOI 10.1111/j.1471-4159.2007.04990.x
127. Yu L, Huang Z, Mariani J et al (2004) Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med 10:1081-1087
128. Sheardown MJ, Knutsen LJS (1996) Unexpected neuroprotection observed with the adenosine A2A receptor agonist cgs 21680. Drug Dev Res 39:108
129. von Lubitz DK, Lin RC, Jacobson KA (1995) Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur J Pharmacol 287:295-302
130. Jones PA, Smith RA, Stone TW (1998) Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience 85:229-237
131. Jones PA, Smith RA, Stone TW (1998) Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res 800:328-335
132. Sitkovsky MV, Ohta A (2005) The 'danger' sensors that STOP the immune response: The A2 adenosine receptors? Trends Immunol 26:299-304
133. Mayne M, Fotheringham J, Yan HJ et al (2001) Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49:727-735
134. Latini S, Corsi C, Pedata F et al (1995) The source of brain adenosine outflow during ischemia and electrical stimulation. Neurochem Int 27:239-244
135. Pugliese AM, Coppi E, Spalluto G et al (2006) A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. Br J Pharmacol 147:524-532
136. von Lubitz DK, Lin RC, Popik P et al (1994) Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol 263:59-67
137. Palmer TM, Benovic JL, Stiles GL (1995) Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. J Biol Chem 270:29607-29613
138. Trincavelli ML, Tuscano D, Marroni M et al (2002) A3 adenosine receptors in human astrocytoma cells: Agonist-mediated desensitization, internalization, and down-regulation. Mol Pharmacol 62:1373-1384
139. Hentschel S, Lewerenz A, Nieber K (2003) Activation of A(3) receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons. Restor Neurol Neurosci 21:55-63
140. Fedorova IM, Jacobson MA, Basile A et al (2003) Behavioral characterization of mice lacking the A3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol 23:431-447
141. Chen GJ, Harvey BK, Shen H et al (2006) Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res 84:1848-1855
142. Pedata F, Pugliese AM, Coppi E et al (2007) Adenosine in the central nervous system: Effects on neurotransmission and neuroprotection. Immunol Endocr Metab Agents Med Chem 7:304-321